Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BabyTEARS
NCT07499999Phase 2Not yet recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Sep 2026
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in breast cancer comparing Low-Dose Exemestane with Low-Dose Tamoxifen (2 arms). Primary endpoint: Difference in Overall Domain Score Change From Baseline in Menopause-Specific Quality of Life Questionnaire at 12 months. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
exemestanetamoxifen
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07499999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07499999.